The invention relates to a derivative or pharmaceutically-acceptable salt of a GLP-1 analogue containing an amino acid sequence shown in a formula (I). The derivative of the GLP-1 analogue has the function of human GLP-1 analogue, and compared with the human GLP-1 analogue, the derivative has a longer half-life period in vivo. The derivative or pharmaceutically-acceptable salt of the GLP-1 analogue, or the pharmaceutical composition of derivatives containing the GLP-1 analogue or pharmaceutically-acceptable salts thereof can be widely used for treating non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus and obesity. The formula (1) is as follows: X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24-Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-Lys (I).
